Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 185696.53 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 9871.26 Crore, up 14.33 % from last quarter Total Income of Rs 8633.98 Crore and up 27.55 % from last year same quarter Total Income of Rs 7739.04 Crore. Company reported net profit after tax of Rs 1408.65 Crore in latest quarter.
Investment Rationale
The brokerage remains positive on SUN Pharma on the back of: a) its strategy of NCE-led brand building in developed markets, b) industry leading market share in the Branded Generics market of DF, EM, and RoW, c) its Complex Generics pipeline and improving operating leverage
Promoter/FII Holdings
Promoters held 54.5 per cent stake in the company as of June 30, 2021, while FIIs held 11.5 per cent, DIIs 22 per cent and public and other 12.1 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
